HOXA1 Is an Antagonist of ERα in Breast Cancer

Area of Science:

• Oncology
• Molecular Biology
• Genomics

Background:

• Breast cancer is a leading cause of female cancer mortality globally.
• Estrogen receptor alpha (ERα) is expressed in about 70% of breast cancers.
• HOX proteins, critical for development, are implicated in oncogenesis, with HOXA1 being a key player.

Purpose of the Study:

• To investigate the relationship between HOXA1 and ERα expression in breast cancer.
• To elucidate the functional interaction and antagonism between HOXA1 and ERα.
• To explore the potential role of HOXA1 in endocrine therapy resistance.

Main Methods:

• Bioinformatic analysis of genome-wide mRNA expression profiles from public breast cancer datasets.
• In vitro experiments to assess HOXA1's effect on ERα activity.
• Investigation of molecular mechanisms, including DNA-binding domains, NF-κB activation, HOXA1-PBX interaction, and physical interaction.

Main Results:

• A strong inverse correlation was found between HOXA1 and ERα expression, affecting 2,486 genes, suggesting functional antagonism.
• HOXA1 was demonstrated to inhibit ERα activity in vitro.
• Inhibition requires an intact HOXA1 DNA-binding homeodomain and involves DNA-binding independent NF-κB activation.
• HOXA1-PBX interaction is not involved in ERα inhibition, though physical interaction occurs but is not essential for inhibition.

Conclusions:

• HOXA1 and ERα exhibit functional antagonism in breast cancer.
• HOXA1's inhibition of ERα activity is a complex process involving its DNA-binding domain and NF-κB activation.
• HOXA1 may contribute to endocrine therapy resistance in ERα-positive breast cancer, presenting a potential therapeutic target.